ROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India

Simple item page
dc.contributor.authorShukla, Sen_US
dc.contributor.authorPandey, RKen_US
dc.contributor.authorKant, Sen_US
dc.contributor.authorGarg, Ren_US
dc.contributor.authorHusain, Nen_US
dc.date.accessioned2020-04-10T01:50:25Z
dc.date.available2020-04-10T01:50:25Z
dc.date.issued2019-09
dc.description.abstractBackground: C-ros oncogene 1, receptor tyrosine kinase (ROS 1) proto-oncogene 1, receptor tyrosine kinase (ROS-1) fusions are potent oncogenic drivers and these re-arrangements promote signal transduction programs leading to uninhibited cell survival and proliferation identified in 1–2% of cases of nonsmall-cell lung cancer. Mesenchymal epithelial transition factor (MET) receptor tyrosine kinase and its ligand are predominantly involved in epithelial mesenchymal transition and tissue regeneration. The MET amplification and overexpression is oncogenic in 3–7% cases. The objectives of this study were to identify the frequency of ROS-1 and c-MET protein expression in adenocarcinoma lung and to correlate it with the clinicopathological parameters and to analyze the histomorphology of cases that harbor the characteristic mutations (c-MET and ROS-1). Materials and Methods: Study group comprised a prospective cases series of 90 cases of adenocarcinoma lung. ROS-1 protein expression was determined by immunohistochemistry using the D4D6 rabbit monoclonal antibody (Cell Signaling, Danvers, MA) and c-MET protein expressed was analyzed using the SP-44 clone (Ventana Medical Systems). Results: c-MET protein expression was identified in 33.33% cases (n = 30/90) with statistically significant thyroid transcription factor-1 (TTF-1) positivity. ROS-1 protein expression was detected in 3.33% cases (n-3/90), in biopsies from the respiratory tree with TTF-1 expression. Conclusion: This is the first study from the Indian subcontinent to identify the frequency of ROS-1 re-arrangements and MET amplification in the Indian population. The availability of targeted therapy that has a significant impact on survival makes it essential to detect these less frequent mutations.en_US
dc.identifier.affiliationsDepartment of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsDepartment of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationShukla S, Pandey RK, Kant S, Garg R, Husain N. ROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India. Indian Journal of Pathology and Microbiology. 2019 Sep; 62(3): 433-436en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/196366
dc.languageenen_US
dc.publisherIndian Association of Pathologists and Microbiologistsen_US
dc.relation.issuenumber3en_US
dc.relation.volume62en_US
dc.source.urihttps://dx.doi.org/10.4103/IJPM.IJPM_754_18en_US
dc.subjectImmunohistochemistryen_US
dc.subjectmesenchymal epithelial transitionen_US
dc.subjectnonsmall cell lung carcinomaen_US
dc.subjectROSen_US
dc.subjecttargeted therapyen_US
dc.titleROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North Indiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpm2019v62n3p433.pdf
Size:
2.01 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology